Lorna Hopcroft

*This is an algorithmically generated author record based on publicly available information.

Research Subjects

Research Interests

Lorna Hopcroft has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

Simon T. Barry
Bioscience, Early Oncology, AstraZeneca, Cambridge, United Kingdom
21 shared publications
Susana Ros
Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK
21 shared publications
Cath Eberlein
AstraZeneca 1 Small Molecule Bioscience, Oncology Targeted Discovery, Oncology R&D Cambridge, United Kingdom
18 shared publications
Eleanor M. Wigmore
Centre for Genomics Research, AstraZeneca
18 shared publications
Valentina Cutano
Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic
18 shared publications
Adam Spruce
Cancer Research Horizons, Cancer Research UK, Cambridge, United Kingdom
17 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
Cited by 1
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
List of names and affiliations for individuals associated with the Functional Gemonics Centre FGC.
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Data from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
List of names and affiliations for individuals associated with the Functional Gemonics Centre FGC.
Cited by 1
Open Access
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
Extended analysis of epigenomic landscape in ER+ breast cancer cells treated with capivasertib.
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S10 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
Extended analysis of epigenomic landscape in ER+ breast cancer cells treated with capivasertib.
Open Access
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
Capivasertib sensitizers are enriched for members of epigenetic regulator families.
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S2 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
Capivasertib sensitizers are enriched for members of epigenetic regulator families.
Open Access
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
Characterisation and validation of Cas9-expressing ER+ breast cancer cell and quality assessment of the CRISPR screening data.
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S1 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
Characterisation and validation of Cas9-expressing ER+ breast cancer cell and quality assessment of the CRISPR screening data.
Open Access
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
Capivasertib resistant cells characterization.
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S5 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
Capivasertib resistant cells characterization.
Open Access
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
KDM5C and KAT6A KO increases effectiveness of capivasertib.
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S3 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
KDM5C and KAT6A KO increases effectiveness of capivasertib.
Open Access
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
KDM5 and KAT6A/Bi sensitize ER+BC cells to AKT inhibition.
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S4 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
KDM5 and KAT6A/Bi sensitize ER+BC cells to AKT inhibition.
Open Access
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
Inhibition of KDM5 and KAT6A/B with small molecules restores capivasertib response in resistant ER+ breast cancer cells.
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S6 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
Inhibition of KDM5 and KAT6A/B with small molecules restores capivasertib response in resistant ER+ breast cancer cells.
Open Access
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
Gene expression changes following KDM5C a in combination with capivasertib.
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S7 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
Gene expression changes following KDM5C a in combination with capivasertib.
Open Access
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
Effects on pathway biomarker responses following treatment of KDM5C and KAT6A KO cells with capivasertib and fulvestrant and the combination.
Website
Google Scholar
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S8 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
by Valentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, Eleanor M. Wigmore, Qing Wu, Lambert Montava Garriga, Lorna Hopcroft, David Esopi, Michele Chirichella, Siyu Liu, et al.
Effects on pathway biomarker responses following treatment of KDM5C and KAT6A KO cells with capivasertib and fulvestrant and the combination.

Show all